Posts by founder

  • Mymetics Corporation

    Mymetics' Promising HIV Vaccine Candidate Obtains Funding to Begin Study at Texas Biomedical Research Institute


    http://finance.yahoo.com/news/…-candidate-221500280.html


    EPALINGES, SWITZERLAND--(Marketwired - Sep 29, 2014) - Mymetics Corporation (MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.

    Research to be funded by the Bill & Melinda Gates Foundation

    The study will be led by Dr. Ruth Ruprecht, Scientist & Director of the Texas Biomed AIDS Research Program. This new study follows a successfully completed smaller study at the Institute of Laboratory Animal Science (ILAS) in Beijing, China in which a two-component vaccine protected all monkeys against repeated AIDS virus exposures from persistent infection - an unprecedented result.1 One of the vaccine components further showed a strong safety and tolerance profile in a Phase I clinical trial in human volunteers.2

    Dr. Ruth Ruprecht said, "Mymetics' HIV vaccine candidate is unique in its design. First, it uses building blocks from a special part of the HIV envelope protein, called gp41, and second, it was engineered to stop HIV from crossing the mucosal barriers - with promising initial results. We are extremely proud that this study is to be funded by the Bill & Melinda Gates Foundation. We hope to confirm the previous findings and learn more about this vaccine's mechanism of action in providing mucosal protection."

    Ronald Kempers, CEO of Mymetics, commented, "We are very honored and pleased about our collaboration with Dr. Ruth Ruprecht, a leading expert in the HIV field. This collaboration and funding represents an important milestone and recognition of the work performed by the Mymetics team and partners over the last years and provides a basis to further develop our HIV vaccine candidate."

    He added: "After the signing of the license and collaboration agreement earlier this year for our Respiratory Syncytial Virus vaccine candidate which is funded by Astellas Pharma, this new funding and collaboration for our HIV vaccine candidate is another confirmation that we are on the right track and are building a strong foundation for success with the right partners."

    New trial to begin October 2014

    With its HIV-1 (human immunodeficiency virus type 1) vaccine candidate, produced through its proprietary virosome technology and judicious antigen design, Mymetics aims to provide both a first line of defense through mucosal protection as well as a second line of defense against infection through the generation of blood antibodies. The new trial, to begin in October 2014, will involve 36 rhesus monkeys (n=12 per group) and compare two antigen vaccination regimens with placebo, followed by intra-vaginal challenges with live virus that carries an envelope that differs from the one in the vaccine preparation. Results are expected at the end of 2015.


    About HIV and the Mymetics vaccine approach

    2.3 million new people were infected by HIV in 2012 while an estimated 1.6 million people died of AIDS in that year (source:WHO). HIV-related illness remains one of the leading global causes of death and is projected to remain so in the coming decades. There is as yet no vaccine available against HIV. However, results of a large Phase III clinical study in Thailand showed a modest protective effect of 31%, providing encouraging support for the feasibility of an effective HIV vaccine. The Thai study tested unrelated HIV vaccine candidates and was reported in September 2009 in the New England Journal of Medicine.

    Traditional approaches to creating a vaccine against HIV have aimed to elicit specific blood antibodies or CTLs (cytotoxic T cells). Both approaches have been largely unsuccessful to date, and importantly, no or very little protection has been seen with heterologous challenges, in which the virus strain differs from the original vaccine. A CTL response has the further drawback of requiring infection to have already occurred. Despite their importance as protection mechanisms, neither approach is suitable for protecting against initial mucosal transmission of HIV.

    A vaccine that blocks HIV transmission across mucosal membranes represents a highly promising approach to preventing HIV infection; however, few studies have focused on this approach, until now. It builds however on the findings that certain people are not infected with HIV, even though they are exposed to it very frequently. Women and men who produce IgA antibodies against the HIV gp41 protein in their mucosal secretions have been found to display resistance to HIV transmission and infection. Mymetics has used its technology and expertise to design a vaccine candidate specifically intended to induce a mucosal antibody response against HIV while also inducing blood antibodies.

    About Mymetics

    Mymetics Corporation (MYMX) is a Swiss-based biotechnology company registered in the US and trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process.

    Mymetics develops next-generation preventative vaccines for infectious diseases. Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.

    Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, intranasal Influenza, Malaria, Herpes Simplex Virus and the RSV vaccine (out licensed to ClearPath - Astellas). The company's intranasal Influenza vaccine and the HIV-1 vaccine have successfully completed Phase I clinical trials in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase. For further information, please visit mymetics.com.

    About Texas Biomedical Research Institute

    Texas Biomed, formerly the Southwest Foundation for Biomedical Research, is one of the world's leading independent biomedical research institutions dedicated to advancing health worldwide through innovative biomedical research. Located on a 200-acre campus on the northwest side of San Antonio, Texas, the Institute partners with hundreds of researchers and institutions around the world to develop vaccines and therapeutics against viral pathogens causing AIDS, hepatitis, herpes, hemorrhagic fevers, and parasitic diseases responsible for malaria, schistosomiasis and Chagas disease. The Institute also has programs in the genetics of cardiovascular disease, diabetes, obesity, psychiatric disorders and other diseases. For more information on Texas Biomed, go to www.TxBiomed.org.

    Forward looking statements

    The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.

  • Mymetics Corporation

    Astellas to Form Strategic Partnership

    http://finance.yahoo.com/news/…-clearpath-112511741.html


    TOKYO, JAPAN and ROCKVILLE, MD and EPALINGES, SWITZERLAND--(Marketwired - Jan 6, 2014) - Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas' goal of building a global vaccine franchise and launched its first company, RSV Corporation (RSVC), in December 2013. Astellas will fund RSVC's development of a virosome vaccine technology, licensed from Mymetics Corporation (Mymetics - OTCBB:MYMX), for respiratory syncytial virus (RSV) through completion of a Phase 2b human proof-of-concept study. Based on the strategic partnership, Astellas received exclusive rights to acquire RSVC as well as further develop and commercialize the vaccine product.

    "This partnership highlights our commitment to build a global vaccine business and represents a highly efficient model for bringing innovative vaccines to market. It is also a unique opportunity for Astellas to utilize external cutting edge science and technology to enhance our ability to generate innovative drugs, as part of the "Reshaping Research Framework" program announced in May, 2013," said Kenji Yasukawa, Senior Vice President and Chief Strategy Officer, Astellas.

    RSV is a respiratory pathogen which infects patients of all ages. The infection can be especially severe in infants and older adults with chronic pulmonary or cardiovascular disease. Each year the virus infects 64 million people and is responsible for 160,000 deaths worldwide. Currently, there is no vaccine available for this virus.

    "Together we are harnessing our collective resources to accelerate development of this promising, early stage asset and will replicate this scalable, outcome driven model across future portfolio companies," said Chuck Finn, PhD, Chairman, ClearPath Development Company.

    Mymetics will collaborate with RSVC on the development of the vaccine, with Toon Stegmann PhD, CSO of Mymetics, remaining engaged on pre-clinical activities including nonclinical evaluation, formulation development, and manufacturing. RSVC's development team is led by George Siber, MD, a recognized vaccine expert with more than 35 years experience. From 1996 to 2007, Dr. Siber was Executive Vice President and Chief Scientific Officer of Wyeth Vaccines Research where he oversaw the approval and marketing of six childhood vaccines including Prevnar, Meningitec, Rotashield and FluMist.

    "The financial backing and commercial experience of Astellas combined with ClearPath's development expertise and our continued program involvement are unique factors which all work to increase the likelihood of success," said Ronald Kempers, CEO, Mymetics. "We anticipate RSV will be the first of many vaccine constructs that can be generated from our proprietary 2nd generation virosome platform."

    For its technology for RSV, Mymetics could receive upfront and post proof-of-concept milestone payments up to $82 million, as well as double digits royalties and other payments.

    The virosome vaccine consists of membrane nanoparticles containing the native key viral surface proteins that are targets of the immune system, but lack the genetic material required to cause infection. In pre-clinical testing, it generated powerful immune responses and strong protection against RSV. Virosome-based vaccines have a proven track record of safety and efficacy for the prevention of other infections including influenza.


    About Astellas Pharma Inc.:

    Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 17,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious diseases, Oncology, Neuroscience and DM Complications and Kidney diseases. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en.


    About ClearPath Development Company:

    ClearPath Development Company, a subsidiary of RRD International, works with leading biopharmaceutical companies to expand product pipeline opportunities with complementary development and finance capabilities. Its business model provides biopharmaceutical companies with an alternative mechanism for accelerating product development. This model is highly capital-efficient for development of early-stage assets, enables accelerated development for existing company assets and external assets under consideration for in-licensing, and helps de-risk development projects with tailored financing structures. For more information, visit www.clearpathdevco.com.


    About Mymetics Corporation:


    Mymetics Corporation is a Swiss-based biotechnology company registered in the US (MYMX) developing next-generation preventative vaccines for infectious diseases. The company's vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. The Mymetics pipeline also includes vaccines to prevent influenza (intranasally administered), HIV-1 and malaria. Please visit www.mymetics.com.


    Forward-looking statements

    The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to successfully develop our vaccine candidates, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.

    Contact:

    Astellas Pharma Inc.
    Corporate Communications
    Phone +81-3-3244-3201
    ClearPath Development Company
    Lisa Fels
    703.739.2424 x110
    lfels@brightlinestrategies.com
    Mymetics
    Christophe Lamps
    Office +41 22 308 2222
    Mobile +41 79 476 2687
    cla@dynamicsgroup.ch
    Mymetics
    USA: Michelle Linn
    Phone: +1 774 696 38 03
    linnmich@comcast.net

  • Mymetics Corporation

    Mymetics' HIV-1 Innovative Vaccine is Safe

    http://finance.yahoo.com/news/…s-one-show-073000012.html



    EPALINGES, SWITZERLAND--(Marketwire - Feb 21, 2013) - Results from a randomized study published in PLOS ONE(1) today demonstrate that Mymetic'' innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine is safe and well tolerated and demonstrates a high level of immunogenicity in a Phase I trial involving 24 healthy women. The publication highlights that vaccine-induced mucosal antibodies may contribute to reduce sexually transmitted HIV-1. Mymetics Corporation (MYMX) is a pioneer in the development of vaccines that use the human mucosal system, the body''s first line of defense, to prevent transmission of infectious diseases.


    Ronald Kempers, CEO of Mymetics, commented: "These results in female volunteers strongly confirm the validity of our innovative approach and represent a major milestone for the development of a prophylactic HIV-1 vaccine capable of establishing an efficient front-line defense at the mucosal level. Preclinical studies in non-human primates already generated extremely promising data demonstrating 100% protection against multiple intra-vaginal challenges with a live virus."


    Providing Mymetics obtains additional sources of financing for this project, the company plans to test its prophylactic HIV-1 vaccine candidate in a combined Phase I and II trial to investigate an additional HIV-1 antigen and a further optimized vaccine formulation.


    All vaccinated women rapidly developed lipopeptide P1-specific serum antibodies, confirming the high efficacy of the influenza virosome as carrier/adjuvant for inducing a Th2 (T helper type 2) response. This antibody concentration represents billions of molecules of antibodies in the vaginal secretion and it is believed to be sufficient for preventing sexually transmitted HIV-1 within the first minutes or hours following the virus entry in the vaginal cavity.


    "The vaccine is designed for blocking the virus passage across the mucosal tissues or stopping early cell infections at the mucosal site from where it could spread and reach other immune organs and destroy the immune system," added Sylvain Fleury, Chief Scientific Officer of Mymetics.


    Until the completion of this double blind, randomized, placebo controlled Phase I trial, the capacity of an HIV-1 vaccine to induce mucosal antibodies in the genital and rectal tracts of women after intramuscular and intranasal administrations was unknown. This Phase I study confirms Mymetics'' previous pre-clinical study conducted on non-human primates, which was published in February 2011 in the journal Immunity.


    About Mymetics


    Mymetics Corporation is a Swiss-based biotechnology company registered in the US (MYMX) developing next-generation preventative vaccines for infectious diseases.


    The company''s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.


    Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex Virus. The company''s HIV-1 vaccine has completed a Phase I clinical trial in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while the HSV vaccine candidate is in the preclinical phase. The RSV vaccine candidate is expected to enter a Phase I trial beginning 2014. The Influenza vaccine has finished a Phase 1 with Solvay Pharmaceuticals (now Abbott).


    Being 100% privately funded and financed by its main shareholders, the company is currently exploring several new investment and partner opportunities to secure financing to further advance the development of its vaccines.


    The link to the PLOS ONE article: http://dx.plos.org/10.1371/journal.pone.0055438.


    For further information, please visit www.mymetics.com.


    Forward-looking statements


    The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics'' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.


    (1) Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

    Contact:

    Mymetics Corporation
    Ronald Kempers
    CEO
    +41 21 653 4535
    www.mymetics.com
    Media: Dynamics Group
    Christophe Lamps
    Senior Partner
    Mobile: +41 79 476 2687
    cla@dynamicsgroup.ch

  • Mymetics Corporation

    Mymetics' Phase Ib Malaria Vaccine: safe and well tolerated

    EPALINGES, SWITZERLAND--(Marketwire - 06/17/10) - Mymetics Corporation, a pioneer in the development of vaccines preventing early transmission of human infectious diseases, announced today that its innovative Malaria vaccine has successfully completed a Phase Ib clinical trial in Tanzania. The study confirms that the company's virosome-based vaccine is well tolerated and safe for adults and children as young as 5 years of age. The vaccine induced specific, long-lasting antibody responses against the key AMA-1 and CSP-1 Malaria antigens in semi-immune subjects, lasting up to 12 months for CSP-1.


    Mymetics' Malaria vaccine uses influenza-based virosomes as the antigen carrier -- already approved as a vaccine carrier in more than 40 countries -- with two synthetic peptide vaccine components that mimic the native structure of important antigens found during the key stages in the Malaria parasite's life cycle.


    In the Phase Ib trial, conducted in cooperation with the Swiss Tropical and Public Health Institute (Swiss TPH) and Pevion Biotech Ltd., the vaccine was tested during a 12-month period on 40 healthy, semi-immune volunteers (32 children, 8 adults) in Tanzania under endemic conditions. Each subject received two injections that were well tolerated by both adults and children as young as 5 years of age, without any safety issues.


    The results showed a high sero-conversion rate for most subjects. The highest percentage of long-lasting sero-converted children following injection of the vaccine was 70% at day 180 for the AMA-1 antigen (against the merozoite), while for the CSP-1 antigen (against the sporozoite) 83% of children were positive for up to 365 days.


    "These exciting results are especially promising compared to previous clinical studies, as the group was semi-immune and the trial was carried out without special precautions to avoid parasite exposure -- conditions that normally make it very difficult to trigger a strong immune response," said Professor Marcel Tanner, Director of the Swiss Tropical and Public Health Institute.


    "Mymetics' Malaria vaccine is one of only a few that target the blood and liver stages of the Malaria parasite's life cycle, an approach we believe is more likely to achieve efficacy in providing protection and parasitemia control," added Sylvain Fleury, CSO of Mymetics Corporation.


    Following this successful Phase Ib trial, Mymetics is now preparing the next phase of development of the multi-stage vaccine with additional promising Malaria antigens. While achieving sterile immunity is the ideal objective, a vaccine that efficiently reduces or controls liver and erythrocyte infection could also reduce parasitemia and symptoms, significantly decreasing mortality and morbidity in children. Mymetics is working closely with not-for-profit organizations to fund these next stages of development.


    Mymetics Corporation acquired the Malaria program, including this study, from Pevion Biotech in October 2007. The clinical trial was initially launched by Pevion Biotech Ltd. and the Swiss Tropical and Public Health Institute. The study was performed at the Bagamoyo Research & Training Centre (BRTC) of the Ifakara Health Institute (IHI), Tanzania, under the leadership of Dr. Blaise Genton and Dr. Salim Abdulla.


    About Mymetics

    Mymetics Corporation is a Swiss-based biotechnology company registered in the US (OTC.BB:MYMX - News) developing next-generation preventative vaccines for infectious diseases. Mymetics' core technology and expertise are the use of virosomes, lipid-based carriers containing functional fusion viral proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection. Mymetics is led by an international and experienced management team and is supported by a strong Scientific Advisory Board composed of renowned experts. The company has established contacts with world leaders in vaccine development.


    Mymetics currently has 5 vaccines in its pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex Virus. The company's HIV vaccine is entering a new proof-of-concept preclinical trial following unprecedented results in a first study, and is also currently in a Phase I clinical trial in human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been successfully completed, while RSV and HSV vaccine candidates are in the preclinical phase. The Influenza vaccine has been out-licensed to Solvay Pharmaceuticals (now Abbott). For further information, please visit http://www.mymetics.com.


    About the Swiss Tropical and Public Health Institute

    Founded in 1943, the Swiss Tropical Institute (STI) has become a world-renowned institution for teaching, research and services in the field of International Health Development. In June 2009 the Institute for Social and Preventive Medicine of the University of Basel, internationally recognized in the areas of environmental epidemiology and women's health, was integrated into the STI, and since 2010 the whole institution has publicly taken on a new name, the Swiss Tropical and Public Health Institute, also to be known as the Swiss TPH. Over 500 colleagues from 40 countries work worldwide for the Swiss TPH in research, teaching and service provision, with the single goal to facilitate and contribute to health development worldwide, with a strong focus on underdeveloped countries.


    Forward looking statements

    The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.




    http://finance.yahoo.com/news/…-4097886362.html?x=0&.v=1

  • Mymetics Corporation

    First Human Vaccinations of Mymetics' Preventative HIV

    The First Human Vaccinations of Mymetics' Preventative HIV Vaccine Candidate are Well Tolerated.


    Press Release Source: Mymetics Corporation On Tuesday January 19, 2010, 8:00 am EST


    EPALINGES, Switzerland, Jan. 19, 2010 (GLOBE NEWSWIRE) -- Mymetics Corporation, a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced today that following the vaccination of human volunteers as part of a clinical Phase I trial, the company’s first preventative HIV vaccine has been well tolerated.


    This Phase I trial follows the breakthrough results Mymetics has achieved in macaque monkeys last year. During these pre-clinical studies Mymetics' HIV vaccine provided full protection of vaccinated non-human primates against multiple heterologous live virus challenges, while the placebo group became fully infected. These levels of protection have not been seen before in this type of HIV studies.


    HIV, the virus that causes AIDS, infected about 2.7 million new people in 2008, while an estimated 2 million people died in that same period. HIV related illness remains one of the leading causes of death globally and is projected to continue as a significant global cause of premature mortality in the coming decades.


    Until now there has been no vaccine against HIV. "Mymetics vaccine approach is unique in the sense it aims to build protection at the mucosal layer, which is the largest port of entry for many pathogens," stated Jacques Francois Martin, CEO of Mymetics Corp.


    "The start of this first Phase I is a very important step for Mymetics in its development of a successful preventative HIV vaccine," stated Sylvain Fleury, Chief Scientific Officer of Mymetics Corp. The placebo controlled, double blinded, single site trial will study the safety and tolerance of the Mymetics HIV preventative vaccine in healthy volunteers. During the last four weeks, the first people have been successfully vaccinated and the vaccine was very well tolerated. In total 24 people will be vaccinated and monitored over a 12 month period.


    About Mymetics


    Swiss based, US biotechnology company (OTCBB:MYMX - News) focused on the development of the next generation preventative vaccines for infectious diseases, with 5 vaccines in the pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex Virus. Mymetics core technology and know-how is based on the use of virosomes in combination with rationally designed antigens to induce protection acting on early transmission and infection events, including the mucosal immune response as a first barrier against the infection. Mymetics believes this approach allows it to develop preventative vaccines for a broad range of diseases.


    Mymetics has started a Phase I for its HIV-1 vaccine. The Phase 1b clinical trial for the Malaria vaccine with children in Tanzania has been completed, while the RSV and the HSV vaccine candidates are in pre-clinical phase. The Influenza virus is out-licensed to Solvay Pharmaceuticals (now Abbott). For further information, please visit: http://www.mymetics.com

  • Mymetics Corporation

    ground breaking results with preventative HIV vaccine

    http://www.mymetics.com/index.…:press-releases&Itemid=21




    October 20 2009 - Mymetics Corporation presents ground breaking results with preventative HIV vaccine at the World AIDS Vaccine Congress in Paris 19 – 22 October


    Epalinges, Switzerland October 20th 2009 – Mymetics Corporation, a pioneer in the development of mucosal focused vaccines for human infectious diseases, announced today that the company had been selected to present their ground breaking results obtained for their preventative HIV-1 vaccine.


    The poster is titled “High Protection of Female Macaques from Repeated Intra-Vaginal Challenges with Low-dose of SHIVSF162P3 upon Mucosal Vaccination with Gp41 subunits-Virosomes inducing Gp41-specific Mucosal Immune Responses”. Results show high mucosal protection against repeated live SHIV vaginal challenges after vaccination with Mymetics’ preventative HIV-1 vaccine candidate. The vaccinated group showed no detectable viremia while the placebo group became fully infected.


    “We are very pleased to share our results with the scientific community attending to the world leading congress on AIDS vaccines” commented Dr. Sylvain Fleury, Chief Scientific Officer of Mymetics Corp, “the results are very encouraging and we believe Mymetics’ approach is opening the door to the development of preventative HIV-1 vaccine through mucosal defense mechanism”.


    About Mymetics

    Swiss based, US biotechnology company (NASDAQ OTC BB: MYMX), focused on the development of the next generation preventative vaccines for infectious diseases, with 5 vaccines in the pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex Virus. Mymetics core technology and know-how is based on the use of virosomes as a vaccine delivery platform combined with rationally designed antigens to induce protection acting on early transmission and infection events, including the mucosal immune response as a first barrier against the infection. Mymetics believes that this platform allows it to develop preventative vaccines for a broad range of diseases.


    Mymetics will start the Phase I for HIV-1 vaccine. The Malaria vaccine is at the end of a Phase 1b trial with children in Tanzania, while the RSV and the HSV vaccine candidates are in pre-clinical phase. The Influenza virus is out-licensed to Solvay Pharmaceuticals. For further information, please visit: http://www.mymetics.com


    Forward looking statements

    The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.[/url]

  • Mymetics Corporation

    Mymetics Corporation

    A Delaware corporation, listed on the NASDAQ exchange and directed from Nyon Switzerland, Mymetics Corp. (OTCBB:MYMX) announces the confirmation of the success of its preventive vaccine against HIV/AIDS. To date, these results are the most promising and advanced in the world. Further, they confirm a decisive path towards the prevention of transmitting HIV/AIDS. These results are of such significance that the European authorities have authorised a phase 1 clinical trial on humans.


    NYON, Switzerland, February 9, 2009 -- Mymetics (http://www.mymetics.com) Corporation (OTCBB: MYMX),announced today that on February 11, in Montreal, at the 16th world Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Sylvain Fleury, Chief Scientific Officer of Mymetics, will present the results of a second series of preclinical trials that confirm the success of its preventive vaccine against HIV/AIDS.


    It is widely recognized that certain people exist that are naturally resistant to the HIV/AIDS infection and in particular an identified group of prostitutes in Kenya and Cambodia. These identified prostitutes have been followed for the past 13 years and have provided recurrent blood samples. Despite their exposure to multiple HIV positive individuals, these women remain HIV negative. The explanation for this natural resistance is well known, these prostitutes are protected by antibodies present in their vaginal secretions.


    The same resistance has been noted in males who have naturally occurring neutralizing antibodies in their rectal secretions.


    Mymetics' have concentrated their research towards replicating this natural protection and to develop similar antibodies qualified as mucosal secretions (IgA antibodies in the vaginal secretions) as compared to blood antibodies (IgG antibodies circulating in the blood).


    Thus, the preventive vaccine formulation developed by Mymetics specifically induces the production of IgA antibodies, whereas all the other vaccine antidotes are aimed at the production of IgG antibodies in the blood. It is this fundamental difference in approach that explains the success of Mymetics' research compared to the announced failures of other research laboratories. As a result, Mymetics' vaccine stimulates a defence mechanism effectively blocking entry of the virus at the mucosal level, the gateway to entry and infection of humans.


    The completion of the preclinical tests (on the monkeys) is achieved through a viral test (viral challenge) for which Mymetics chose the Chinese Macaqua Mulata species of monkey as they most closely resemble humans in virus transmission. One group is vaccinated and the other is used as reference group. Then, the two groups receive several doses of the virus, the goal being to establish that the vaccinated group resists the infection and that the non-vaccinated group becomes infected by the virus.


    The results of the recent viral test, carried out in Beijing, could not have been more compelling: the vaccinated group either proved 100% resistant to the virus or remained at a non detectable level, whereas the non-vaccinated group were completely infected.


    Moreover, the results obtained in July 2008 at the Institute of Animal Laboratory Science (ILAS) of the Chinese Academy of Science, were verified by an independent laboratory, the Center for Diseases Control (CDC) of Beijing. The CDC employed a measurement technique five times more precise than that of the ILAS. The high degree of specificity and quality of these second series of results confirming the original observations is all the more impressive.


    Based on these most promising results and the excellence of the research, the Belgian Health Ministry acting on behalf of the European Authority, authorised expeditiously (16 days) the approval to commence Phase I Human Clinical Trials.


    In order to avoid the potential criticism of the low number of animals in the two test groups, Mymetics presented its results to Prof. Chris Miller of the University of California (UC Davis), whose laboratory is considered by the scientific community the best center of preclinical studies on macaques. Dr. Miller is the Leader of the Virology and Immunology Unit at the California Regional Primate Research Center (CRPRC) and has been part of the simian AIDS research effort at the CRPRC since 1987. Qualifying their results as excellent, Dr. Miller confirmed his agreement for his laboratory to complete further studies on groups of macaques.


    Through its heterologous viral challenge results, unique in the world, Mymetics affirms its position of leader in the mucosal approach of producing neutralizing antibodies, whereas the research of the other laboratories is almost singularly concentrated on blood antibodies. The objective of the new study with Dr. Chris Miller is to obtain indisputable results and to accelerate research and human clinical trials of Mymetics vaccine. As the prevention of the HIV/AIDS on a global scale is a primary goal of Mymetics, time is now of the essence.

  • Mymetics Corporation

    Mymetics Corporation Retains Lazard Bank

    NYON, Switzerland, Dec. 9, 2008 (GLOBE NEWSWIRE) -- Mymetics Corporation (OTCBB:MYMX), announced today that it has retained Lazard as its financial advisor to provide the company with independent advice on strategic transactions, tactical acquisitions and other financial matters for the period 2009 to 2011.


    "With the unfailing support of a small group of Swiss investors, we have raised CHF 32 million over the last 3 years, and thanks to those investors we have been able to achieve decisive breakthroughs in the development of a preventative vaccine for HIV/AIDS. Not wishing to remain a single product company, we acquired a Malaria vaccine using the same delivery system (virosome) as our HIV/AIDS vaccine," stated Christian J. F. Rochet, President and CEO of Mymetics, who added, "the advice and the support of Lazard will enable us to achieve the second phase of our development, which will be primarily reflected in 2009 through strategic acquisitions and partnerships."


    About Lazard


    Lazard, one of the world's preeminent financial advisory and asset management firms, operates from 41 cities across 24 countries in North America, Europe, Asia, Australia, Central and South America. With origins dating back to 1848, the firm provides advice on mergers and acquisitions, restructuring and capital raising, as well as asset management services to corporations, partnerships, institutions, governments, and individuals.


    About Mymetics Corporation


    Mymetics' corporate objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including HIV/AIDS and Malaria. In Q4 2008 Mymetics will commence Phase 1b Human Clinical trials of their HIV/AIDS preventative vaccine candidate which showed extremely promising results (see Press Release September 16, 2008) as well as continuing Mymetics' long term Malaria vaccine in Phase II Human Clinical trials. Additional applications of Mymetics' research include potential treatments and/or vaccines for human oncoviral leukemias, multiple sclerosis, and organ transplantation. Long range growth plans key to Mymetics' development include acquisitions of prophylactic or therapeutic vaccines against breast cancer, candidiasis, RSV, malaria and hepatitis.


    das scheint sich einiges zu tun, was meint ihr?

  • Von Roll

    Von Roll

    Bank Von Roll wird konkret


    Von Roll am Anfang einer neuen Ära


    Erste Akquisitionen in Sicht – «Bank Von Roll» ein Thema – Mut zum Risiko könnte belohnt werden


    Von Beat D. Hebeisen


    Coilwinding heisst die weltweit grösste Fachmesse für Elektroisolationen. Seit Dienstag dieser Woche trifft sich die Branche zu diesem jährlichen Stelldichein in Berlin. Für Von Roll ist diese Veranstaltung ideal, um den Puls der Industrie zu fühlen. An der Messe gebe es keine Hinweise auf eine Abflachung, fasst VR-Präsident und CEO Thomas Limberger die ersten Eindrücke aus Gesprächen mit Kunden und Konkurrenten zusammen. Von Roll selbst geht es offenbar glänzend. Nach einem Plus von 13% im ersten Quartal läge der Umsatz auch in den drei Monaten per Ende Juni «deutlich» über dem Markt, skizziert der CEO die Situation im Gespräch mit «Finanz und Wirtschaft».


    Den Anlegern blieb die Situation nicht verborgen: Der Aktienkurs stieg seit Anfang Jahr 35%. Der neue Grossaktionär, die Familie von Fink, ist an dieser Entwicklung nicht unschuldig. Sie kontrolliert seit der ausserordentlichen Generalversammlung im August 2007 das Unternehmen und hat kraft der Stimmenmehrheit auch den Verwaltungsrat mit Personen aus den eigenen Reihen besetzt.


    Diskretere Informationspolitik


    Zentrale Person in diesem Gremium ist Limberger. Nicht einmal 24 Stunden nach der Wahl hatte er sich vor zehn Monaten den Medien gestellt und in blumigen Worten geschildert, welche Ziele er mit dem Unternehmen verfolgt. Ausser dem Ausbau des Stammgeschäfts stellte er den Aufbau neuer Geschäftsfelder in Aussicht. Er sprach von Wachstumsmärkten wie Wasseraufbereitung, Beschichtungsapplikation und Laser-High-Tech-Systemen. Seither ist es stiller geworden um den Deutschen. Er hat sich an den Rat aus seinem Umfeld gehalten und die PR-Maschine in eigener Sache zurückgefahren. Die Investoren wünschen mehr Fakten als Worte.


    Das heisst aber nicht, dass im Hintergrund nicht intensiv an den vorgegebenen Zielen weitergearbeitet worden wäre. Die Verbesserung der operativen Abläufe brachte höhere Margen. Die von Limberger anvisierten Zukäufe wurden vorangetrieben. Mit dem Neugeld aus der Kapitalerhöhung sind Zukäufe bis zu 1,3 Mrd. Fr. möglich. Das Auswahlverfahren ist weit fortgeschritten. Mit Kandidaten würden erste Schriftstücke ausgetauscht, beschreibt Limberger den Stand der Verhandlungen. Konkreter will er nicht werden, es werde aber kaum mehr sehr lange dauern, bis Namen genannt werden könnten.


    Limberger verfolgt weiterhin das Projekt einer Bank. Unter der Marke Von Roll soll ein Institut positioniert werden, das sich auf Anlagemöglichkeiten für vermögende Einzelpersonen und Familien konzentriert. Im Unterschied zu anderen Banken will sich der Konzernchef auf klassische Anlagestrategien beschränken. Strukturierte Produkte sind für ihn kein Thema. Das Industrie-Know-how der Von Roll soll für klassische Investitionen in die Schweizer Industrie sowie weltweit genutzt werden. Es sei indes nicht die Idee, eine Bank für die Familie von Finck zu schaffen.




    Erfolgslatte hoch angesetzt


    Den Investor interessiert zurzeit v. a. die operative Entwicklung der Von Roll. Hier gilt es zu unterscheiden zwischen dem Stammgeschäft und den Visionen für die Zukunft. Die Mittel aus der Kapitalerhöhung werden in Unternehmen investiert, die ein Mindestwachstum von 10% pro Jahr, eine Betriebsgewinnmarge in gleicher Höhe sowie einen Ertrag auf dem investierten Kapital von mindestens 20% erreichen . Ohne Details zu kennen, ist hier eine Wertung schwierig. Der Bereich Elektroisolationen profitiert vom steigenden Stromverbrauch. Beachtlich ist zudem der Ersatzbedarf an Elektroinstallationen in den nächsten Jahren. Die Branche rechnet mit Wachstumsraten um 6%. Von Roll selbst will den Umsatz im Stammgeschäft bis 2012 verdoppeln und die Ebit-Marge auf 14% (2007: 7,1%) verbessern – anspruchsvolle Ziele.


    Wir sind etwas zurückhaltender und erwarten für die nächsten zwei Jahre eine Umsatzsteigerung um 12%. Dank operativer Verbesserungen sind für das Jahr 2009 eine Ebit-Marge von 10,5% sowie ein Gewinn von 89 Mio. Fr. realistisch. Das hohe Kurs-Gewinn-Verhältnis 2009 von 26 signalisiert, dass die Börse von den anstehenden Akquisitionen eine wesentliche Gewinnverbesserung erwartet. Das KGV würde dadurch dementsprechend sinken. Wir sind überzeugt, dass Limberger Von Roll in eine neue Umsatz- und Ertragsliga führen wird. Das einzig störende an der Situation ist, dass ein Investor zurzeit die «Katze im Sack» kauft. Wer Mut zum Risiko hat, wird in diesem Fall aber wohl belohnt.


    Von Stahl zu von Finck


    Einst war Von Roll als Stahlunternehmen ein Begriff. 1996 wurde der Stahlbereich mit von Moos zu Swiss Steel fusioniert. Die restliche Von Roll agierte unglücklich und stand 2003 nahe am Konkurs. Nach einer umfassenden Restrukturierung besteht die Gesellschaft nun mehrheitlich aus Geschäften der ehemaligen Isola-Werke, die 1987 aus Gründen der Diversifikation gekauft wurden. Von Roll ist heute spezialisiert auf die Produktion von Isolationsbändern, Kupferdrähten, Harzen sowie Lacken für Generatoren und Motoren. Im Angebot sind auch Verbundstoffe für verschiedene industrielle Anwendungen.


    An der Spitze der Gesellschaft kam es Mitte 2007 zu einem Machtwechsel. Die deutsche Milliardärsfamilie um August von Finck erhöhte die Beteiligung an Von Roll von 21 auf 31,6%. Ziel dieser Aktion war es, an einer ausserordentlichen Generalversammlung eine Kapitalerhöhung um 323 Mio. Fr. durchzubringen und die Mehrheit im Verwaltungsrat zu erreichen. Beides gelang (vgl. FuW Nr. 63 vom 15. August 2007). Als Verwaltungsratspräsident und CEO übernahm Thomas Limberger die Verantwortung – Limberger war zuvor CEO von OC Oerlikon.


    Die aufgelegte Kapitalerhöhung wurde von den Aktionären nicht voll gezeichnet. Von Finck sprang in die Lücke, überschritt damit die Marke von einem Drittel des Kapitals und musste in der Folge den anderen Aktionären ein Übernahmeangebot unterbreiten. Obwohl die Offerte absichtlich niedrig tief angesetzt war, wurden dem Grossaktionär fast 30% des restlichen Kapitals angedient. Dadurch erhöhte sich die Beteiligung der Familie von Finck auf beachtliche 63,1%. DH


    Quelle: Finanz und Wirtschaft

  • Mymetics Corporation

    Mymetics Corporation (OTCBB: MYMX),

    a vaccine development company, made the acquisition of a preventive malaria vaccine from Pevion Biotech AG, a privately-held biotech company based in Switzerland.


    Entwickelt Impfstoffe für Malaria, HIV usw.


    Was meint ihr zu dieser Firma?


    http://www.mymetics.com